» Articles » PMID: 29418077

Case of Advanced Pulmonary Squamous Cell Carcinoma Cured by Resection Through Preoperative Induction of Immune Checkpoint Inhibitor

Overview
Journal Thorac Cancer
Date 2018 Feb 9
PMID 29418077
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The options for lung cancer treatment have increased due to the development of immune checkpoint inhibitors, but there has been no report of inoperable cases whereby the treatment effects rendered the case operable, an operation was subsequently performed, and histological assessment of the surgical specimen was carried out. Here, we report a 67-year-old man who was given pembrolizumab for T3N0 lung squamous cell carcinoma suspected of pericardial infiltration and judged inoperable. Treatment effect was evaluated after four courses. Computed tomography indicated a partial response, and operability was feasible. Therefore, thoracoscopic left upper lobectomy was performed after six courses of pembrolizumab, and histological assessment of the treatment effect was determined to be Ef 3, a complete response. The postoperative course was uneventful and he was discharged on the third postoperative day. We encountered a case that could be surgically treated after pembrolizumab administration. This treatment was safe and effective for advanced lung cancer.

Citing Articles

Prognostic Significance of Glycolysis-Related Genes in Lung Squamous Cell Carcinoma.

Kadasah S Int J Mol Sci. 2024; 25(2).

PMID: 38256214 PMC: 10816031. DOI: 10.3390/ijms25021143.


Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient.

Okano Y, Kunishige M, Kondo Y, Kadota N, Morishita A, Naruse K Thorac Cancer. 2021; 13(3):510-513.

PMID: 34931476 PMC: 8807244. DOI: 10.1111/1759-7714.14293.


Our experience of lung resection in patients who decline blood transfusion for religious reasons.

Takagi H, Muto S, Yamaguchi H, Mine H, Ozaki Y, Okabe N Gen Thorac Cardiovasc Surg. 2021; 69(7):1105-1111.

PMID: 33550544 PMC: 8203515. DOI: 10.1007/s11748-021-01589-2.

References
1.
Villaruz L, Socinski M . The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy. Clin Pharmacol Ther. 2016; 100(3):212-4. PMC: 4982801. DOI: 10.1002/cpt.385. View

2.
Zago G, Muller M, van den Heuvel M, Baas P . New targeted treatments for non-small-cell lung cancer - role of nivolumab. Biologics. 2016; 10:103-17. PMC: 4975160. DOI: 10.2147/BTT.S87878. View

3.
Khoja L, Kibiro M, Metser U, Gedye C, Hogg D, Butler M . Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. Br J Cancer. 2016; 115(10):1186-1192. PMC: 5104887. DOI: 10.1038/bjc.2016.308. View

4.
Elias A, Kasi P, Stauffer J, Thiel D, Colibaseanu D, Mody K . The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study. Front Oncol. 2017; 7:121. PMC: 5466999. DOI: 10.3389/fonc.2017.00121. View